Back to top

Analyst Blog

Zacks Equity Research

BMY/Sanofi Alliance Modified

SNY BMY

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Following the genericization of blood thinner Plavix and hypertension treatment Avapro/Avalide in major markets across the globe, partners Bristol-Myers Squibb Company (BMY - Analyst Report) and Sanofi (SNY - Analyst Report) revamped their long-standing alliance regarding the drugs. The new agreement will be effective from January 1, 2013.

The restructured agreement will see Sanofi selling Avapro/Avalide globally and Plavix in all markets except the US and Puerto Rico. Bristol-Myers will be responsible for selling Plavix in these markets until December 2019. Per the modified agreement, Bristol-Myers will receive royalties on the total sales (branded plus generic) of Plavix (barring the US and Puerto Rico) as well as Avapro/Avalide (global) from Sanofi until December 2018. The end of 2018 will see Bristol-Myers receiving a payment of $200 million from Sanofi.

The companies stated further that all disputes related to the alliance have been resolved. The resolution of the dispute will see Bristol-Myers shelling out a one-time payment of $80 million to Sanofi. The payment relates to the disruption in Avalide supply in the US last year.  

We remind investors that Plavix and Avapro/Avalide went off patent in US in May 2012 and March 2012, respectively. The loss of exclusivity of these drugs in the US hurt Bristol-Myers’ second quarter 2012 results with net sales declining 18% to $4.44 billion. US sales of Plavix plummeted 60% to $701 million in the second quarter of 2012 (global sales were also down 60% to $741 million). US sales of Avapro/Avalide were down 85% to $20 million during the second quarter of 2012.

We expect Bristol-Myers’ results in the third quarter 2012 (scheduled to be announced on October 24) to be impacted adversely by the genericization of Plavix in the US.

Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions and is introducing new products to augment its product portfolio. The Amylin buy in August 2012, through which Bristol-Myers expanded its presence in the lucrative diabetes market, is an effort to combat the substantial revenue losses due to Plavix’s genericization in the US.

Neutral on Bristol-Myers/Sanofi

Currently, we have a long-term Neutral recommendation on Bristol-Myers. The stock carries a Zacks #3 Rank (Hold rating) in the short run. We have a similar long-term recommendation on Sanofi, which carries a Zacks #2 Rank (Buy rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.41 +4.97%
NETFLIX INC NFLX 347.72 +4.92%
BOFL HOLDING BOFI 85.20 +4.85%
RAMBUS INC RMBS 12.33 +4.58%
CELL THERAPE CTIC 3.11 +3.93%